Ketamine for Treatment-resistant Depression: A Multicentric Clinical Trial in Mexican Population

Multicentre, randomised, triple-blind, parallel-group trial assessing efficacy of a single 0.5 mg/kg IV ketamine infusion compared with saline placebo in adults with treatment-resistant major depressive disorder.

Primary purpose is treatment; dosing is a single 40-minute IV infusion with standard safety monitoring at three national health provider clinics in Mexico.